Teva stopped negotiations with US on a compromise deal on the price coordination suspicion

Teva last month stopped negotiations on a compromise with the US Department of Justice's antitrust unit on suspicion that the company had inflated US generic drug prices and was engaged in price coordination and sharing market shares with its competitors in this market, the New York Times reports.
According to the report, the U.S. Department of Justice will decide in the coming days whether to file a lawsuit against Teva though government officials have yet to lose hope that a settlement agreement will be reached. It is estimated that the Trump administration will not dare to file a lawsuit against the company - which is the U.S.'s largest supplier of generic drugs - in the midst of the Corona epidemic.
Teva has positioned itself as willing to volunteer free drugs to treat plague victims, as it did in March when it announced it would donate 6 million tablets of Hydroxychloroquine by the end of March and more than 10 million tablets within a month.
The original outline of the drug is for the treatment of malaria and lupus, but during the Corona crisis, Trump personally pushed for her treatment of corona patients, although later studies did not reveal clinical efficacy.
The New York Times claims that a week or two before Teva stopped talks about a compromise agreement, he approached White House Roberto Miniona, a member of the Teva board of directors, with a proposal that Teva would help the administration discuss the assistance the company is ready to submit to the government. Miniona appealed to one of his friends during the college term of Jared Kushner, Trump's son-in-law, and asked for government assistance to get a license to export the hydroxychloroquine drug from India and coordinate with its competitors its marketing and distribution.
The U.S. Department of Justice has been investigating for four years and 40 U.S. states have begun legal proceedings against Teva and 16 other generic companies on suspicion of inflating generic drug prices through price coordination, market distribution and coordinated tenders - all at the expense of US taxpayers insured by policies Federal and Private Medical Insurance.
Nature and other generic companies were sued in May 2019 by 40 states in the U.S. Of up to 1,000% the prices of 112 drugs, and matched the prices of another 86 drugs with other generic companies.
The lawsuit also seeks US officials to evade evidence and disrupt investigative proceedings by text messaging and version coordination with representatives of other generic companies. The lawsuit filed in May 2019 significantly expanded a previous lawsuit filed against Teva and other generic companies in December 2016, alleging that Teva and six companies Other generics were involved in a market share and a concerted increase in the prices of antibiotic drugs for acne, and a blood sugar control drug for diabetics. The US Department of Justice was able to raise guilt and fines $ 224 million from four generic drug companies.